Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity
- PMID: 15911925
- DOI: 10.1177/1534735405276191
Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity
Abstract
Preclinical and clinical studies suggest that anthracycline-induced cardiotoxicity can be prevented by administering coenzyme Q10 during cancer chemotherapy that includes drugs such as doxorubicin and daunorubicin. Studies further suggest that coenzyme Q10 does not interfere with the antineoplastic action of anthracyclines and might even enhance their anticancer effects. Preventing cardiotoxicity might allow for escalation of the anthracycline dose, which would further enhance the anticancer effects. Based on clinical investigation, although limited, a cumulative dose of doxorubicin of up to 900 mg/m2, and possibly higher, can be administered safely during chemotherapy as long as coenzyme Q10 is administered concurrently. The etiology of the dose-limiting cardiomyopathy that is induced by anthracyclines can be explained by irreversible damage to heart cell mitochondria, which differ from mitochondria of other cells in that they possess a unique enzyme on the inner mitochondrial membrane. This enzyme reduces anthracyclines to their semiquinones, resulting in severe oxidative stress, disruption of mitochondrial energetics, and irreversible damage to mitochondrial DNA. Damage to mitochondrial DNA blocks the regenerative capability of the organelle and ultimately leads to apoptosis or necrosis of myocytes. Coenzyme Q10, an essential component of the electron transport system and a potent intracellular antioxidant, appears to prevent damage to the mitochondria of the heart, thus preventing the development of anthracycline-induced cardiomyopathy.
Similar articles
-
Exposure to anthracyclines during childhood causes cardiac injury.Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019. Semin Oncol. 2006. PMID: 16781284 Review.
-
Pharmacologic prevention of anthracycline-induced cardiomyopathy.Cardiol Rev. 2009 Sep-Oct;17(5):243-52. doi: 10.1097/CRD.0b013e3181b8e4c8. Cardiol Rev. 2009. PMID: 19690476 Review.
-
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.Cancer Treat Rev. 2004 Nov;30(7):643-50. doi: 10.1016/j.ctrv.2004.06.002. Cancer Treat Rev. 2004. PMID: 15531396 Review.
-
Inhibitory effects of several anthracyclines on mitochondrial respiration and coenzyme Q10 protection.Drugs Exp Clin Res. 1985;11(8):533-7. Drugs Exp Clin Res. 1985. PMID: 3869924
-
Pathogenesis of cardiotoxicity induced by anthracyclines.Semin Oncol. 2006 Jun;33(3 Suppl 8):S2-7. doi: 10.1053/j.seminoncol.2006.04.020. Semin Oncol. 2006. PMID: 16781283 Review.
Cited by
-
Chemotherapy-related Cardiomyopathy.Eur Cardiol. 2015 Jul;10(1):19-24. doi: 10.15420/ecr.2015.10.01.19. Eur Cardiol. 2015. PMID: 30310418 Free PMC article. Review.
-
MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling.Genes Dev. 2020 Apr 1;34(7-8):526-543. doi: 10.1101/gad.334219.119. Epub 2020 Feb 20. Genes Dev. 2020. PMID: 32079652 Free PMC article.
-
Effect of fullerenol C(60)(OH) (24) on lipid peroxidation of kidneys, testes and lungs in rats treated with doxorubicine.Eur J Drug Metab Pharmacokinet. 2012 Dec;37(4):301-7. doi: 10.1007/s13318-012-0092-y. Epub 2012 Apr 24. Eur J Drug Metab Pharmacokinet. 2012. PMID: 22527972
-
Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling.Oncogene. 2009 Nov 5;28(44):3880-91. doi: 10.1038/onc.2009.242. Epub 2009 Aug 17. Oncogene. 2009. PMID: 19684617 Free PMC article.
-
The Central Role of Amino Acids in Cancer Redox Homeostasis: Vulnerability Points of the Cancer Redox Code.Front Oncol. 2017 Dec 21;7:319. doi: 10.3389/fonc.2017.00319. eCollection 2017. Front Oncol. 2017. PMID: 29312889 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
